建立先天性A型血友病患者死亡评估框架并应用于不良事件报告数据库
该研究通过文献综述、FAERS数据库分析和专家意见,建立了一套用于先天性A型血友病(PwcHA)患者死亡评估的框架与算法。将算法应用于2000年至2020年FAERS数据,最常见死因为出血(22.2%)和血栓形成(10.4%)。该框架有助于一致、客观地评估死亡率,支持统一方法的应用。
要点
- 建立先天性A型血友病患者死亡评估框架,涵盖出血、血栓等HA相关死因及一般人群常见死因。
- 应用FAERS数据验证,出血(22.2%)和血栓形成(10.4%)为最常见报告死因。
- 该框架可用于新疗法风险-获益评估和安全性信号识别。
核心结论
- 提出一个用于评估接受任何血友病治疗的PwcHA患者死亡率的概念框架,可一致且客观地分析死亡事件。
- 应用FAERS数据表明各血友病治疗报告的死亡模式基本一致,支持该统一方法的效用。
研究设计与样本
- 通过文献综述、分析美国FDA不良事件报告系统(FAERS)数据库及专家见解,识别PwcHA已知死亡原因并开发评估算法。
- 将算法应用于FAERS数据库2000年1月1日至2020年3月31日的死亡数据作为概念验证。
主要发现
- PwcHA与非HA人群共享死亡原因,包括心血管疾病、恶性肿瘤、感染、肺部疾病、痴呆和创伤/自杀。
- 与HA相关的死亡原因包括出血、血栓形成、人类免疫缺陷病毒、丙型肝炎病毒和肝功能障碍。
- FAERS数据分类显示,最常见死因为出血(22.2%)和血栓形成(10.4%)。
关键数值与推荐
- FAERS死亡数据中出血占22.2%,血栓形成占10.4%(2000年1月1日至2020年3月31日)。
临床怎么用
- 该框架可用于新疗法引入时对PwcHA患者死亡风险的一致评估和比较。
- 有助于及时识别新出现的安全性信号并全面评估风险-获益特征。
局限性
- FAERS数据为自发报告,可能存在报告偏倚和不完整性。
- 框架基于文献、FAERS和专家意见开发,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A (PwcHA) remains below that of the non-HA population. As new therapies are introduced, a uniform approach to the assessment of mortality is required for comprehensive evaluation of risk-benefit profiles, timely identification of emerging safety signals, and comparisons between treatments. OBJECTIVES: Develop and test a framework for consistent reporting and analysis of mortality across past, current, and future therapies. PATIENTS/METHODS: We identified known causes of mortality in PwcHA through literature review, analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, and expert insights. Leading causes of death in general populations are those recognized by the Centers for Disease Control and Prevention and the World Health Organization. We developed an algorithm for assessing fatalities in PwcHA and used this to categorize FAERS data as a proof of concept. RESULTS: PwcHA share mortality causes with the non-HA population including cardiovascular disease, malignancy, infections, pulmonary disease, dementias, and trauma/suicide. Causes associated with HA include hemorrhage, thrombosis, human immunodeficiency virus, hepatitis C virus, and liver dysfunction. We propose an algorithm employing these classes to categorize fatalities and use it to classify FAERS fatality data between 01/01/2000 and 03/31/2020; the most common causes were hemorrhage (22.2%) and thrombosis (10.4%). CONCLUSIONS: A conceptual framework for examining mortality in PwcHA receiving any hemophilia therapy is proposed to analyze and interpret fatalities, enabling consistent and objective assessment. Application of the framework using FAERS data suggests a generally consistent pattern of reported mortality across HA treatments, supporting the utility of this unified approach.
引用
- Pipe SW, Kruse-Jarres R, Mahlangu JN, et al. Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database. J Thromb Haemost. 2021. PMID: 33331042. doi:10.1111/jth.15186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。